Identification and characterization of lLF2 as a prognostic biomarker in HER2-positive breast cancer using Mendelian randomization and machine learning
ILF2 is biologically and clinically important in HER2-positive breast cancer, and its high expression is linked with tumor immune escape and increased resistance to chemotherapeutic agents. Future studies should further explore the mechanism and application of ILF2 as a potential therapeutic target.
Authors
- Huimei Yi
- Xiyun Quan
- Ming Li (ORCID: https://orcid.org/0000-0002-2540-1738)
- Meiyuan Huang
- Yi Deng (ORCID: https://orcid.org/0000-0001-5357-5877)
Institutions
- Central South University (CN)
- Zhuzhou Central Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1007/s12672-025-03762-y
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province